Merck & Company: Evaluating A Drug Licensing Opportunity

edf40wrjww2CF_PaperMaster:Desc
Should Merck license the compound?    
    Merck would be responsible for     
        1) the approval of Davanrik
        2) the manufacture of Danavrik
        3) marketing of Danavrik
    Merck would pay LAB for    
        1) initial fee
        2) royalty on all sales
        3) make additional pymts as Danavrik completed each stage of approval process (3 Phases)
    Additional facts:    
        approval process should take 7 years
        patent will cover 17 years (7 of approval process nad 10 yr period of exclusivity beginning in yr 7)
1    Assumptions:    
        All Cash flows are expressed as after tax present values discounted to time zero, including capital expenditures
        At any point "failure," investment decision is to stop funding
        Assuming Standard deviation of 0.5
        Using T= 7 years in Black-Scholes Valuation                        

2    Decision Tree                            
        See wo ...
Word (s) : 3616
Pages (s) : 15
View (s) : 6719
Rank : 0
   
Report this paper
Please login to view the full paper